Low molecular weight heparin for the treatment of acute ischemic stroke;Niedermolekulares heparin: Eine soforttherapie des schlaganfalls?

Nervenarzt

Volumn 67, Issue 10, 1996, Pages 886-887

  Sporer, B ^a   Haberl, R L ^b  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b Munich Municipal Hospital   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

LOW MOLECULAR WEIGHT HEPARIN;

ACUTE DISEASE; CEREBROVASCULAR DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG ADMINISTRATION; DRUG EFFECT; HUMAN; LETTER; MORTALITY; NEUROLOGIC EXAMINATION; RANDOMIZED CONTROLLED TRIAL; SURVIVAL RATE; TREATMENT OUTCOME;

ACUTE DISEASE; CEREBROVASCULAR DISORDERS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; NEUROLOGIC EXAMINATION; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 0030255675     PISSN: 00282804     EISSN: None     Source Type: Journal    
DOI: 10.1007/s001150050068     Document Type: Article

References (13)

1. Becker M, Menger MD, Lehr H-A (1994) Heparin-released superoxide dismutase inhibits postischemic leukocyte adhesion to venular endothelium. Am J Physiol 267: H925-H930
2. Duke RJ, Bloch RF, Turpie AGG, Trebilock R, Bayer N (1986) Intravenous heparin for the prevention of stroke progression in acute partial stable stroke: a randomized control trial. Ann Intern Med 105: 825-828
3. Herbert JM, Maffrand JP (1991) Effect of pentosan polysulphate, standard heparin and related compounds on protein kinase C acitivity. Biochim Biophys Acta 1091: 432-441
4. Carter CJ, Kelton JG, Hirsh J, Cercus A, Santos AV, Gent M (1982) The relationship between hemorrhagic and antithrombotic properties of low molecular weight heparin in rabbits. Blood 59: 1239-1245
5. Itoh K, Nakao A, Kishimoto W, Takagi H (1995) Heparin effects on superoxide production by neutrophils. Eur Surg Res 27: 184-188
6. Andriuoli G, Mastacchi R, Barbanti M, Sarret M (1995) Comparison of the antithrombotic and haemorrhagic effects of heparin and a new low molecular weight heparin in rats. Haemostasis 15: 324-330
7. Prins MH, Sing AK, van Herde LR, den Ottolander GJH (1989) Prophylaxis of venous thrombosis with a low-molecular-weight heparin (Kabi 2165/Fragmin) in stroke patients. Haemostasis 19: 245-250
8. Sandercock PAG, van den Belt AGM, Lindley RI, Slattery J (1993) Antithrombotic therapy in acute ischemic stroke: an overview of the completed randomised trials. J Neurol Neurosurg Psychiatry 56: 17-25
9. Turpie AGO, Hirsh J, Jay MR, Andrew M, Hull RD, Levine MN, Carter CJ, Powers PJ, Magnani HN, Gent M (1987) Double-blind randomised trial of ORG 10172 low-molecular-weight heparinoid in prevention of deep-vein thrombosis in thrombotic stroke. Lancet 8532: 523-526
10. Kay R, Wong KS, Yu YL, Chan YW, Tsoi TH, Ahuja AT, Chan FL, Fong KY, Law CB, Wong A, Woo J (1995) Low-molecular-weight heparin for the treatment of acute ischemic stroke. N Engl J Med 333: 1588-1593
11. Cerebral Embolism Study Group (1983) Immediate anticoagulation of embolic stroke: a randomized trial. Stroke 14: 668-676
12. Rothrock JF, Dittrich HC, McAllen S, Taft BJ, Lyden D (1989) Acute anticoagulation following cardioembolic stroke. Stroke 20: 730-734
13. Haley EC, Kassell NF, Torner JC (1988) Failure of heparin to prevent progression in progressive ischemic infarction. Stroke 19: 10-14